GordonMD Global Investments LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002039349

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 14 positions · Total reported value $166.47M · Top-10 concentration 85.7% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.7% · 2 new · 6 cut · 4 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -14.1% · vs SPY -16.2% · Prev Value $206.66M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -10.2% · vs SPY -12.4% · Latest Value $166.47M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, GordonMD Global Investments LP disclosed 14 equity positions with a combined reported value of $166.47M. The filing implies a focused portfolio: its ten largest positions account for 85.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PYXS ($36.21M), KYTX ($30.74M), TEVA ($15.03M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+2.3pp) and away from Other (-2.3pp).

Versus the prior quarter, GordonMD Global Investments LP opened 2 new positions, trimmed 6 and fully exited 4, a turnover rate of 66.7% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2026 were TNGX ($9.02M), VNDA ($8.97M).

Of the 4 positions fully exited versus the prior quarter, the largest were RARE ($9.65M), SION ($5.98M), CRNX ($4.75M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TNGX TANGO THERAPEUTICS INC · $9.02M
  • VNDA VANDA PHARMACEUTICALS INC · $8.97M

Fully Exited (vs previous quarter)

  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $9.65M
  • SION SIONNA THERAPEUTICS INC · prev qtr: $5.98M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $4.75M
  • INSM INSMED INC · prev qtr: $3.05M

Insider Transactions (Form 4)

Latest GordonMD Global Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-01 Buy Pyxis Oncology, Inc. 5,517,000 — SEC filing

All insider transactions →

Fund Profile

GordonMD Global Investments LP is an SEC-registered 13F filer based in Beverly Hills, CA, United States. As of Q2 2026 it reported 16 US equity positions with a combined value of $206.66M. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: BEVERLY HILLS, CA, United States
  • SEC registration: 801-128434 (status: Approved), registered 2023-08-01
  • Regulatory AUM (Form ADV): $322.27M as of 2026-03-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 1 hedge funds

Portfolio Structure

  • 16 positions · $206.66M reported value (Q2 2026)
  • Top 10 holdings = 83.9% of reported value
  • Largest position: KYTX (KYVERNA THERAPEUTICS INC) at 18.3%
  • Average position size: $12.92M

Sector Tilt

  • Health Care 97.7%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q2 2026: 1 new, 4 added, 2 reduced, 1 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 15.54M $36.21M 21.75%
Form 4 · 1 →
21.75%
Add
2 4.52M $30.74M 18.47%
18.47%
Add
3 379.52K $15.03M 9.03%
9.03%
Reduce
4 279.72K $9.07M 5.45%
5.45%
Hold
5 1.85M $9.02M 5.42%
5.42%
New
6 803.55K $8.98M 5.40%
5.40%
Reduce
7 450.00K $8.97M 5.39%
5.39%
New
8 5.30M $8.48M 5.09%
5.09%
Hold
9 475.47K $8.08M 4.86%
4.86%
Reduce
10 3.13M $8.04M 4.83%
4.83%
Hold
11 51.08K $6.20M 3.72%
3.72%
Add
12 248.00K $6.19M 3.72%
3.72%
Reduce
13 14.51K $6.12M 3.67%
3.67%
Reduce
14 110.50K $5.34M 3.21%
3.21%
Reduce

FAQ

What did GordonMD Global Investments LP buy in 2026-Q3?

In its 2026-Q3 13F filing, GordonMD Global Investments LP reported 14 equity positions worth $166.47M in aggregate; its largest disclosed positions were PYXS ($36.21M), KYTX ($30.74M), TEVA ($15.03M).

How large is GordonMD Global Investments LP's portfolio?

GordonMD Global Investments LP reported $166.47M of long equity holdings across 14 positions as of 2026-Q3. Top-10 holdings account for 85.7% of reported value.

What is GordonMD Global Investments LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/gordonmd-global-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →